Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioequivalence: Overview01:16

Bioequivalence: Overview

1.1K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.1K
Drug Regulation01:25

Drug Regulation

1.5K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.5K
Drug Control Governance: Regulatory Bodies and Their Impact01:03

Drug Control Governance: Regulatory Bodies and Their Impact

200
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
200
Global Regulatory Systems01:28

Global Regulatory Systems

47
Global regulatory systems in bacteria enable rapid and coordinated responses to environmental changes by integrating sensory inputs with gene expression, ensuring efficient adaptation to fluctuating conditions. Key global regulatory mechanisms include regulons, two-component systems, sigma factors, and secondary messengers.Regulons and Global RegulatorsA regulon is a collection of genes and operons controlled by a common global regulator. These regulators enable bacteria to prioritize resource...
47
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

153
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
153
Biopharmaceutics and Pharmacokinetics: Overview01:28

Biopharmaceutics and Pharmacokinetics: Overview

2.2K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
2.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Isolation, purification, structural characterization and immunostimulatory activity of water-soluble polysaccharides from Lepidium meyenii.

Phytochemistry·2018
Same author

Pennogenin tetraglycoside stimulates secretion-dependent activation of rat platelets: evidence for critical roles of adenosine diphosphate receptor signal pathways.

Thrombosis research·2012
Same author

Polymorphisms in the XPG gene and risk of gastric cancer in Chinese populations.

Human genetics·2012
Same author

[Influences of D-galactosamine and lipopolysaccharide on liver tissue regeneration and repair in mice with partial hepatectomy].

Nan fang yi ke da xue xue bao = Journal of Southern Medical University·2012
Same author

Large and giant ventral paraclinoid carotid aneurysms: surgical techniques, complications and outcomes.

Clinical neurology and neurosurgery·2012
Same author

Association of mitochondrial DNA variations with lung cancer risk in a Han Chinese population from southwestern China.

PloS one·2012

Related Experiment Video

Updated: Aug 6, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.8K

Biosimilars: navigating the regulatory maze across two worlds.

Kaikun Wei1, Yazhen Kou1, Hongjin Kan1

  • 1Office for Pharmaceutical Science of Biological Products, Center for Drug Evaluation, National Medical Products Administration, Beijing, China.

Trends in Biotechnology
|March 16, 2023
PubMed
Summary

Biosimilar developers face regulatory hurdles in Europe and China. Understanding these differences is key to successfully entering these major global markets for biologic medicines.

Keywords:
EMAHLX02NMPAbiosimilarregulationtrastuzumab

More Related Videos

Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

17.5K
Author Spotlight: Advancing Biotherapeutic Mass Calculation by Introducing mAbScale, a Python-Based Desktop Application
04:24

Author Spotlight: Advancing Biotherapeutic Mass Calculation by Introducing mAbScale, a Python-Based Desktop Application

Published on: June 16, 2023

1.6K

Related Experiment Videos

Last Updated: Aug 6, 2025

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.8K
Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

17.5K
Author Spotlight: Advancing Biotherapeutic Mass Calculation by Introducing mAbScale, a Python-Based Desktop Application
04:24

Author Spotlight: Advancing Biotherapeutic Mass Calculation by Introducing mAbScale, a Python-Based Desktop Application

Published on: June 16, 2023

1.6K

Area of Science:

  • Pharmacoeconomics
  • Regulatory Science
  • Biotechnology

Background:

  • Established biologic products are nearing loss of market exclusivity, creating significant opportunities for biosimilar market entry.
  • The global biosimilar market is expanding, driven by the demand for more affordable biologic medicines.
  • Navigating diverse international regulatory landscapes poses a substantial challenge for biosimilar developers.

Purpose of the Study:

  • To analyze and compare the regulatory requirements for biosimilar approval in Europe and China.
  • To identify key differences and similarities in the regulatory pathways of these two major markets.
  • To provide insights that can help biosimilar developers streamline market entry strategies.

Main Methods:

  • Comparative analysis of European Medicines Agency (EMA) guidelines and China National Medical Products Administration (NMPA) regulations.
  • Review of relevant scientific literature and regulatory documents.
  • Identification of critical divergence points in data requirements, manufacturing standards, and post-market surveillance.

Main Results:

  • Europe generally has a more harmonized and established biosimilar regulatory framework.
  • China's regulatory pathway for biosimilars has evolved rapidly, with increasing alignment with international standards but retaining unique elements.
  • Specific differences were noted in areas such as clinical trial requirements, analytical testing, and labeling.

Conclusions:

  • A clear understanding of the distinct regulatory landscapes in Europe and China is crucial for biosimilar developers.
  • Strategic planning that accounts for regional regulatory variations can significantly expedite market access.
  • Harmonization efforts, while ongoing, necessitate tailored approaches for each market to ensure successful product launch.